Efficacy and Safety of Ethanol Lock Therapy for the Prevention of Central Line-associated Bloodstream Infections

Stopped early · Not applicable

Conditions studied: Catheter-Related Infections

In brief

Patients on long-term parenteral nutrition (PN) are at high risk for central line-associated bloodstream infections (CLABSI). This study evaluates the efficacy and safety of ethanol lock therapy for CLABSI prophylaxis in adult patients on PN.

Key facts

Study ID

NCT02890875

Run by

Stanford University

People needed

3

Starts

2016-08-01

Expected to finish

2017-03-01

Last updated by the study team

2019-05-02

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients (ages 18-80) on PN with silicone-based central venous catheters

You may not qualify if…

• Weight ≤ 50 kg
• Allergy/hypersensitivity/intolerance to ethanol or heparin
• Pregnancy or breastfeeding
• Patient taking metronidazole, disulfiram, or isoniazid
• History of alcohol abuse
• History of heparin-induced thrombocytopenia (HIT) or have an active hypocoagulable state

Where it is running

• Stanford University — Palo Alto, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.